赢8娱乐糖果配对游戏-官方网站[welcome]


+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Pneumococcal conjugate serotype distribution and predominating role of serotype 3 in German adults with community-acquired pneumonia



Pneumococcal conjugate serotype distribution and predominating role of serotype 3 in German adults with community-acquired pneumonia



Vaccine 38(5): 1129-1136



Implementation of the 7-valent pneumococcal conjugate vaccine (PCV7) in infant vaccination programs has substantially reduced the burden of PCV7 serotypes also in adult community-acquired pneumonia (CAP). Currently, it is unclear, if this extensive herd protection effect can be extrapolated to the additional 6 serotypes included in the 13-valent pneumococcal conjugate vaccine (PCV13), which replaced PCV7 in Germany in 2010. We investigated changing trends for PCV13 serotypes in adult CAP patients between three to seven years after implementation of PCV13 infant immunization in Germany. Between December 2012 and January 2017, urine samples from German adult patients with radiologically confirmed CAP were prospectively collected by the multi-center cohort study CAPNETZ and analyzed by the serotype-specific multiplex urinary antigen detection assay (SSUAD) allowing for the detection of PCV13 serotypes. PCV13 serotypes were found in 59 of 796 (7.4%) patients with all-cause CAP, most prevalent was serotype 3 (30 of 59 patients, 50.8%). All patients with serotype 3-CAP were admitted to hospital and the majority required oxygen at admission (83.3% of patients with serotype 3-CAP versus 50.9% of patients with pneumococcal CAP by other serotypes, p?=?0.005). Compared to SSUAD testing, conventional microbiological workup missed 27 of 30 (90.0%) serotype 3-CAP cases. We could not observe a time trend in the proportions of PCV13 serotypes and serotype 3 in all-cause CAP between 2013 and 2016 (OR trend per year 0.84, 95% CI 0.64-1.11 for PCV13 serotypes and OR trend per year 0.95, 95% CI 0.70-1.28 for serotype 3). Conventional methods underestimate serotype 3-CAP that can cause severe disease. Changes in overall PCV13 coverage were not detected during the years 2013 to 2016, mostly driven by a high proportion of serotype 3.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 069548204

Download citation: RISBibTeXText

PMID: 31761500


Related references

Distribution of 13-Valent pneumococcal conjugate vaccine serotype streptococcus pneumoniae in adults 50?Years and Older presenting with community-acquired pneumonia in Israel. Human Vaccines and Immunotherapeutics 14(10): 2527-2532, 2018

Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay. Vaccine 34(20): 2342-2348, 2016

Pneumococcal serotype 19F conjugate vaccine induces cross-protective immunity to serotype 19A in a murine pneumococcal pneumonia model. Infection and Immunity 71(5): 2956-2959, 2003

Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia. Thorax 67(6): 540-545, 2012

Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE). Vaccine 37(20): 2687-2693, 2019

Pneumococcal aetiology and serotype distribution in paediatric community-acquired pneumonia. Plos one 9(2): E89013, 2014

P82 Antimicrobial resistance and serotype distribution of adult pneumococcal community-acquired pneumonia in Japan. International Journal of Antimicrobial Agents 42: S67-S68, 2013

13-Valent vaccine serotype pneumococcal community acquired pneumonia in adults in high clinical risk groups. Vaccine 36(12): 1614-1620, 2018

Antimicrobial Susceptibility and Serotype Distribution of Streptococcus pneumoniae Isolated from Patients with Community-Acquired Pneumonia and Molecular Analysis of Multidrug-Resistant Serotype 19F and 23F Strains in Japan. Epidemiology and Infection 134(6): 1188-1194, 2006

Antimicrobial susceptibility and serotype distribution of Streptococcus pneumoniae isolated from patients with community-acquired pneumonia and molecular analysis of multidrug-resistant serotype 19F and 23F strains in Japan. Epidemiology and Infection 134(6): 1188-1194, 2006

Serotype distribution in non-bacteremic pneumococcal pneumonia: association with disease severity and implications for pneumococcal conjugate vaccines. Plos one 8(8): E72743, 2013

Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany. Plos one 10(7): E0131494, 2015

Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults. Human Vaccines and Immunotherapeutics 11(7): 1825-1827, 2015

Disease Burden and Etiologic Distribution of Community-Acquired Pneumonia in Adults: Evolving Epidemiology in the Era of Pneumococcal Conjugate Vaccines. Infection and ChemoTherapy 50(4): 287-300, 2018

Streptococcus pneumoniae Serotype Distribution and Pneumococcal Conjugate Vaccine Serotype Coverage among Pediatric Patients in East and Southeast Asia, 2000-2014: a Pooled Data Analysis. Vaccines 4(1): -, 2016





赢8娱乐糖果配对游戏